July 23, 2012 / 9:43 PM / in 6 years

UPDATE 1-Zogenix estimates 2nd-quarter revenue below Street

* Expects Q2 rev $7.9 mln to $8.4 mln vs est $9.01 mln

* Shares down 13 pct after market

July 23 (Reuters) - Zogenix Inc estimated second-quarter net revenue below market expectations, sending its shares down 13 percent after the bell.

The company said in a regulatory filing that it expects revenue to be in the range of $7.9 million to $8.4 million for the second quarter.

Analysts were expecting revenue of $9 million, according to Thomson Reuters I/B/E/S.

Zogenix also said it did not receive any contract revenue for the second quarter due to the termination of a co-promotion agreement for its acute migraine treatment with the U.S. subsidiary of Astellas Pharma.

The company earned contract revenue of $8.5 million in the first quarter of 2012 including milestone payments from Astellas. It received contract revenue of $1.6 million in the first quarter of 2011.

Shares of the San Diego, California-based company were trading at $1.85 after the bell. They closed at $2.12 on Monday on the Nasdaq.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below